Persistence of expression of the TMPRSS2:ERG fusion gene after pre-surgery androgen ablation may be associated with early prostate specific antigen relapse of prostate cancer: Preliminary results Journal Article

  

Authors:	Bonaccorsi, L.; Nesi, G.; Nuti, F.; Paglierani, M.; Krausz, C.; Masieri, L.; Serni, S.; Proietti-Pannunzi, L.; Fang, Y.; Jhanwar, S. C.; Orlando, C.; Carini, M.; Forti, G.; Baldi, E.; Luzzatto, L.
Article Title:	Persistence of expression of the TMPRSS2:ERG fusion gene after pre-surgery androgen ablation may be associated with early prostate specific antigen relapse of prostate cancer: Preliminary results
Abstract:	Background: The recently identified TMPRSS2:ERG fusion gene is a candidate oncogene for prostate cancer (PCa). Subjects and methods: We have tested for the presence of this gene in tumor samples from 84 patients who had radical prostatectomy in 1998-2000. Sixty patients (group A) had surgery only; 24 patients (group B) received androgen ablation therapy for 3 months before surgery. The occurrence of the rearrangement was evaluated by RT-PCR and by fluorescent in situ hybridization analysis. Results: A TMPRSS2:ERG fusion gene was present and expressed, as demonstrated by RT-PCR, in 84% of patients in group A and in 54% of patients in group B (p=0.01). The presence of TMPRSS2:ERG transcripts and the levels of ERG RNA, measured by quantitative Real Time-PCR, did not correlate significantly with clinical and pathologic characteristics of the tumors. In patients of group A, but not in those of group B, ERG expression showed a negative correlation with the Gleason score (p=0.0001). Histochemical analysis showed that ERG expression is limited to tumor cells, and in group A patients (but not in group B patients) it is limited to those glands that express TMPRSS2:ERG. Conclusion: The lower proportion of patients expressing TMPRSS2:ERG in group B suggests that androgen ablation inhibits the expression of TMPRSS2:ERG. Moreover, in group B, but not in group A, patients with expression of the fusion gene had earlier prostate specific antigen recurrence (p=0.007). Although preliminary, the data indicate that tumors in which pre-surgery androgen ablation fails to suppress expression of the fusion gene have a higher risk of recurrence. ©2009, Editrice Kurtis.
Keywords:	controlled study; human tissue; protein expression; treatment outcome; aged; middle aged; human cell; major clinical study; prostate specific antigen; animals; reverse transcription polymerase chain reaction; gene expression; recurrence; cancer therapy; prostate cancer; kaplan-meiers estimate; prostate-specific antigen; prostatic neoplasms; rna; correlation analysis; fluorescence in situ hybridization; preoperative period; gene rearrangement; prostatectomy; quantitative analysis; gene fusion; psa recurrence; tmprss2:erg; transcription factor erg; androgen ablation; fusion gene; scoring system; tmprss2:erg fusion gene; ablation techniques; androgen antagonists; oncogene proteins, fusion
Journal Title:	Journal of Endocrinological Investigation
Volume:	32
Issue:	7
ISSN:	0391-4097
Publisher:	Springer
Date Published:	2009-07-01
Start Page:	590
End Page:	596
Language:	English
DOI:	10.3275/6258
PUBMED:	19494719
PROVIDER:	scopus
DOI/URL:	http://www.scopus.com/inward/record.url?eid=2-s2.0-70949083943&partnerID=40&md5=ee236dbce52b25821ca22bb9b88dcc62
Notes:	--- - "Cited By (since 1996): 4" - "Export Date: 30 November 2010" - "CODEN: JEIND" - "Source: Scopus"

https://synapse.mskcc.org/synapse/works/has_related_data_chk/156